Project Grant R01CA316114
- Federal Grant Award Summary Ferric Contrast, Inc. received a $305,253 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through April 30, 2027. The company is developing iron-based magnetic resonance imaging (MRI) contrast agents as alternatives to gadolinium-based contrast agents (GBCA), addressing concerns regarding gadolinium retention in human bone and tissue. The research leverages iron's natural...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Massachusetts General Hospital a $622,804 Project Grant on June 2, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop quantitative point-of-care magnetic resonance imaging (MRI) technology for breast cancer screening. The project, which extends through March 31, 2030, addresses a critical healthcare need...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $382,449 Project Grant to the University of California, Los Angeles under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 16, 2025, with completion targeted for June 30, 2027. This research project develops and validates advanced dual-nuclei magnetic resonance imaging (MRI) techniques to non-invasively differentiate between recurrent brain metastases (RBM) and radiation-induced necrosis (RN)...
- Federal Grant Award Summary Case Western Reserve University received a $630,108 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective March 13, 2026, with completion targeted for February 28, 2030. The award funds research into theranostic approaches for breast cancer treatment utilizing a novel compound designated AKRO-6QC, which functions as both a targeted fluorescence imaging agent for image-guided...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Michigan Technological University a $1.15 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 20, 2025, for a three-year research initiative extending through July 31, 2028. The award supports development of ratiometric near-infrared (NIR) fluorescent probes utilizing BODIPY dyes to detect viscosity changes and protein aggregation in live cells. These self-calibrating probes will...
- Federal Grant Award Summary Yale University received a $607,690 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded May 6, 2026, with completion targeted for April 30, 2031. The award supports development of a magnetic resonance imaging (MRI)-based platform for high-resolution simultaneous intracellular pH (PHi) and extracellular pH (PHe) imaging in glioblastoma multiforme (GBM), an aggressive and...
- Federal Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco, effective June 1, 2026 through May 31, 2028, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This grant funds research focused on predicting immunotherapy response in cancer patients using hyperpolarized 13C Magnetic Resonance Imaging (MRI). The project addresses critical gaps in current oncology practice by...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $591,419 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. This award supports the development of low molecular weight theranostics targeting cluster of differentiation 38 (CD38) protein for multiple myeloma patients. The research deliverables include creation of an 18-fluorine labeled positron emission tomography (PET)...
- Federal Grant Award Summary The University of Pennsylvania received a $415,623 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning April 16, 2026, with completion targeted for March 31, 2028. The project focuses on developing a low-cost, continuous-flow hyperpolarized magnetic resonance imaging (MRI) device capable of producing highly polarized imaging agents at tracer concentrations suitable for continuous...
This project grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), supports the development of nano-encapsulated manganese oxide (NEMO) particles as novel magnetic resonance imaging (MRI) contrast agents for improved detection of residual breast cancer following neoadjuvant chemotherapy. The research, conducted by West Virginia University Research Corporation in Morgantown, West Virginia, focuses on advancing NEMO particles as a pH-sensitive, tumor-specific contrast agent that targets underglycosylated mucin-1 (uMUC-1) overexpressed in cancer cells. Key deliverables include translational development of improved breast MRI imaging platforms utilizing cutting-edge tools, including microfluidic MRI organ-on-a-chip models for high-throughput in vitro contrast testing and a dual MRI and fluorescence intravital imaging window platform for correlating MRI signals with NEMO particle behavior. The grant, awarded June 2, 2026, with a completion date of May 31, 2031, obligates $484,944.00 in federal funding. The project addresses the clinical challenge of low specificity in standard gadolinium-based MRI contrast agents, which contributes to tumor overestimation and unnecessary mastectomies. By developing contrast agents with higher specificity and equivalent or superior contrast capabilities, this research aims to enable more accurate therapeutic response assessment and advance the translational potential of NEMO particles toward clinical application in breast cancer diagnosis and treatment planning.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $484.9k | 6/5/26 |